Literature DB >> 9661883

Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells.

R Frade1, F Rodrigues-Lima, S Huang, K Xie, N Guillaume, M Bar-Eli.   

Abstract

We previously demonstrated that highly metastatic human melanoma cells secrete a 41 kDa proteinase that cleaves C3, the third component of complement, and shares antigenic determinants with procathepsin-L. Thus, we herein transfected the nonmetastatic DX-3 melanoma cells with the procathepsin-L cDNA. Three clones expressing and secreting high levels of procathepsin-L were selected. Conditioned medium and whole cell extracts from these clones, but not from control cells, carried a high C3-cleaving activity. The transfected clones displayed up to 60% resistance to complement-mediated lysis. Overexpression of procathepsin-L in melanoma cells increased their tumorigenicity and switched their phenotype from nonmetastatic to highly metastatic cells. This is the first report that demonstrates that enforced expression of procathepsin-L by human melanoma cells arms them with the ability to inactivate complement-mediated lysis and contributes to tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661883

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Authors:  Dhivya R Sudhan; Maria B Rabaglino; Charles E Wood; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2016-04-07       Impact factor: 5.150

3.  Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways.

Authors:  Lorena Urbanelli; Francesco Trivelli; Luisa Ercolani; Eleonora Sementino; Alessandro Magini; Brunella Tancini; Raffaella Franceschini; Carla Emiliani
Journal:  Mol Cell Biochem       Date:  2010-06-04       Impact factor: 3.396

4.  Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity.

Authors:  Didier Jean; Nathalie Guillaume; Raymond Frade
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

Review 5.  Cathepsin proteases in Toxoplasma gondii.

Authors:  Zhicheng Dou; Vern B Carruthers
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion.

Authors:  G Amuthan; G Biswas; S Y Zhang; A Klein-Szanto; C Vijayasarathy; N G Avadhani
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

7.  Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo.

Authors:  Joseph L Sottnik; Janet C Lori; Barbara J Rose; Douglas H Thamm
Journal:  Clin Exp Metastasis       Date:  2011-08-14       Impact factor: 5.150

8.  Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.

Authors:  Nathalie Guillaume-Rousselet; Didier Jean; Raymond Frade
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

Review 9.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.